A 38-year-old woman with bipolar disorder type I presents with acute suicidal ideation with a plan to harm herself. She has a history of impulsive suicide attempts. Which drug is the first-line choice for acute suicide risk reduction in this patient?

Explanation

## Lithium in Suicide Risk Reduction **Key Point:** Lithium is the only psychotropic agent with robust, level-1 evidence for reducing suicide mortality in mood disorders. It reduces suicide risk by approximately 80–90% in bipolar disorder. **High-Yield:** Lithium's antisuicidal effect is independent of its mood-stabilizing properties and occurs at therapeutic levels (0.6–1.2 mEq/L). This makes it the gold standard for acute and chronic suicide prevention in bipolar disorder. **Clinical Pearl:** Lithium's mechanism for suicide reduction includes: - Increased serotonergic neurotransmission - Reduced impulsivity and aggression - Neuroprotective effects (increased BDNF) - Enhanced neuroplasticity ### Evidence Base | Drug | Suicide Reduction Evidence | Mechanism | Use in Acute Suicidality | |------|---------------------------|-----------|-------------------------| | **Lithium** | Level 1 (RCTs, meta-analyses) | Antisuicidal independent of mood effect | First-line | | Valproate | Level 2 (observational) | Mood stabilization, impulse control | Second-line | | SSRIs | Level 2–3 (mixed evidence) | Antidepressant; may increase risk in young adults | Caution in acute phase | | Antipsychotics | Level 3 (limited evidence) | Acute agitation control only | Adjunctive only | **Mnemonic:** **LITHIUM = Life-saving In Treating Hopelessness In Unipolar and Mood disorders** — the only drug with proven mortality reduction. **Warning:** SSRIs alone are NOT first-line in acute suicidality, especially in bipolar disorder, as they may paradoxically increase suicidal ideation in some patients and risk triggering manic episodes without a mood stabilizer. [cite:Harrison 21e Ch 470]